S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.53
+1.85
+11.09%
NTLA · Intellia Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Intellia Therapeutics Inc (NTLA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$11.64
-0.20
(-1.65%)
● At close: October 21 at 4:00:00 PM EDT
$11.56
-0.09
(-0.77%)
Pre-Market:
4:01:11 AM EDT
DAY'S RANGE
$11.64
$11.55
$11.90
52-WEEK RANGE
$11.64
$7.95
$28.25
What's happening
- NTLA is down 1.65% today, trading at $11.64. — Live quote
- Volume today (194,910) is well below its 3-month average of 4,848,780. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.80 actual vs. $-0.82 estimated (+1.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 10
Hold 7
Sell 2
Strong sell 1
Aggregate ratings for 2026-10-01 (24 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NTLA
+31.70%
vs S&P 500
+18.92%
1-YEAR RETURN
NTLA
-57.68%
vs S&P 500
-72.25%
6-MONTH RETURN
NTLA
-16.38%
3-MONTH RETURN
NTLA
+3.23%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.80
Est. $-0.82
BEAT +1.9%
2026-04-26 (Q1 2026)
$-0.81
Est. $-0.93
BEAT +13.1%
2026-01-26 (Q4 2025)
$-0.83
Est. $-0.97
BEAT +14.8%
2025-10-26 (Q3 2025)
$-0.92
Est. $-1.02
BEAT +10.0%
Valuation Measures & Ratios
Enterprise Value4$1.52B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)27.41
Price / Book73.25
EV4 / Revenue25.63
EV4 / EBITDA—
Profit Margin-672.16%
Operating Margin-711.66%
Return on Equity (ROE8)-57.79%
Return on Assets (ROA9)-47.29%
Avg Volume (3M)4,848,780
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.26B | $1.52B | $1.90B | $968.1M | $736.9M |
| P/E | -5.57 | -3.68 | -4.20 | -1.94 | -1.46 |
| Price/Sales | 44.48 | 25.49 | 35.38 | 20.62 | 11.96 |
| Price/Book | 3.10 | 2.45 | 2.54 | -1.35 | 0.94 |
| EV/Revenue | 42.39 | 23.24 | 31.78 | 17.30 | 9.90 |
| EV/EBITDA | -5.05 | -3.20 | -3.58 | — | — |
| ROE | -55.72% | -66.53% | -60.48% | 69.66% | -64.68% |
| ROA | -47.30% | -54.45% | -48.92% | -55.43% | -51.15% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short45,110,513
Change from Prior Settlement-3.37%
% of Float—
Days to Cover (Short Ratio)9.47
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -46.2% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -672.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -57.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NTLA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $15.0M | $13.8M | $14.2M | $16.6M | $9.1M | $7.0M | $28.9M |
| Operating income | -$112.8M | -$100.5M | -$111.5M | -$110.0M | -$120.8M | -$144.8M | -$139.0M | -$114.0M |
| Net income | -$106.6M | -$96.2M | -$101.3M | -$101.3M | -$114.3M | -$135.7M | -$147.0M | -$107.4M |
| EPS (diluted) | $-0.80 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.34 | $-1.52 | $-1.12 |
| EPS (basic) | $-0.80 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.34 | $-1.52 | $-1.12 |
| Operating margin | -$1.5K | -$668 | -$809 | -$772 | -$727 | -$1.6K | -$2.0K | -$394 |
| Net margin | -$1.4K | -$639 | -$735 | -$711 | -$688 | -$1.5K | -$2.1K | -$371 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $857.2M | $758.8M | $842.1M | $925.3M | $898.9M | $986.2M | $1.19B | $1.17B |
| Total liabilities | $129.5M | $137.8M | $170.7M | $176.9M | $183.6M | $206.2M | $319.1M | $210.7M |
| Stockholders' equity | $727.7M | $620.9M | $671.4M | $748.4M | -$715.3M | $779.9M | $872.0M | $962.6M |
| Total current assets | $527.8M | $466.4M | $527.7M | $581.9M | $495.9M | $551.4M | $639.9M | $710.9M |
| Total current liabilities | $79.4M | $76.4M | $103.9M | $93.7M | $95.5M | $112.6M | $110.9M | $105.7M |
| Cash & equivalents | $106.1M | $134.7M | $155.5M | $193.4M | $156.2M | $126.9M | $189.2M | $120.5M |
| Marketable securities (current) | $331.6M | $241.3M | $294.4M | $317.7M | $303.5M | $376.9M | $412.3M | $537.6M |
| Accounts receivable | $7.3M | $9.1M | $9.5M | $11.1M | $11.4M | $10.5M | $8.5M | $8.9M |
| Marketable securities (non-current) | $190.6M | $141.3M | $155.2M | $158.8M | $170.9M | $203.4M | $260.2M | $286.6M |
| Property, plant & equipment | $15.1M | $15.5M | $17.7M | $20.4M | $22.8M | $25.1M | $27.4M | $28.8M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $11.7M | $18.8M | $20.3M | $13.3M | $9.8M | $12.4M | $14.6M | $13.1M |
| Accrued liabilities | $44.3M | $37.9M | $49.9M | $40.8M | $41.6M | $40.8M | $55.4M | $51.2M |
| Deferred revenue (current) | $0 | $630.0K | $7.3M | $12.2M | $17.2M | $20.7M | $20.7M | $22.2M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $14.0K | $12.0K | $12.0K | $12.0K | $10.0K | $10.0K | $10.0K | $10.0K |
| Retained earnings | -$2.79B | -$2.69B | -$2.59B | -$2.49B | -$2.39B | -$2.29B | -$2.18B | -$2.05B |
| Accumulated other comprehensive income (loss) | -$1.0M | -$240.0K | $1.0M | $990.0K | $653.0K | $1.1M | $605.0K | $3.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$83.1M | -$117.3M | -$69.3M | -$76.9M | -$99.6M | -$148.9M | -$85.2M | -$84.8M |
| Investing cash flow | -$141.6M | $66.3M | $27.5M | -$741.0K | $106.9M | $94.3M | $151.6M | -$7.7M |
| Financing cash flow | $196.1M | $33.6M | $2.0M | $114.9M | $14.7M | $0 | $2.3M | $82.2M |
| Free cash flow | -$84.9M | -$117.4M | -$69.4M | -$76.9M | -$99.9M | -$149.7M | -$86.2M | -$86.1M |
| Capital expenditures | $1.8M | $79.0K | $126.0K | $29.0K | $239.0K | $735.0K | $981.0K | $1.3M |
| Depreciation & amortization | $2.1M | $2.2M | $7.3M | $2.4M | $2.5M | $2.5M | $7.8M | $2.6M |
| Share-based compensation | $18.1M | $13.5M | $16.7M | $19.6M | $22.0M | $21.8M | $39.6M | $39.6M |
| Change in accounts receivable | -$1.8M | -$337.0K | -$1.6M | -$303.0K | $849.0K | $2.0M | -$337.0K | -$3.5M |
| Change in accounts payable | -$7.1M | -$1.4M | $7.0M | $3.5M | -$2.6M | -$1.9M | $1.4M | -$5.6M |
| Purchases of investments | $220.4M | $47.0M | $67.0M | $116.7M | $55.6M | $83.2M | $169.1M | $206.1M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M |
| EPS (diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| EPS (basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Operating margin | -$652 | -$923 | -$1.4K | -$879 | -$810 |
| Net margin | -$610 | -$897 | -$1.3K | -$910 | -$810 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $842.1M | $1.19B | $1.30B | $1.52B | $1.29B |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | — |
| Stockholders' equity | $671.4M | $872.0M | $1.05B | $1.24B | $1.04B |
| Total current assets | $527.7M | $639.9M | $998.3M | $1.22B | $769.3M |
| Total current liabilities | $103.9M | $110.9M | $115.2M | $126.6M | $125.8M |
| Cash & equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M |
| Marketable securities (current) | $294.4M | $412.3M | $685.5M | $669.1M | $625.3M |
| Accounts receivable | $9.5M | $8.5M | $36.5M | $3.8M | $2.0M |
| Marketable securities (non-current) | $155.2M | $260.2M | $99.9M | $69.3M | $337.4M |
| Property, plant & equipment | $17.7M | $27.4M | $32.8M | $27.9M | $21.0M |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $20.3M | $14.6M | $7.5M | $5.2M | $9.7M |
| Accrued liabilities | $49.9M | $55.4M | $67.0M | $60.9M | $43.3M |
| Deferred revenue (current) | $7.3M | $20.7M | $22.1M | $43.8M | $63.8M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $12.0K | $10.0K | $9.0K | $9.0K | $7.0K |
| Retained earnings | -$2.59B | -$2.18B | -$1.66B | -$1.18B | -$703.0M |
| Accumulated other comprehensive income (loss) | $1.0M | $605.0K | -$2.3M | -$7.5M | -$2.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M |
| Investing cash flow | $228.0M | $125.6M | -$31.3M | $160.3M | -$550.8M |
| Financing cash flow | $131.5M | $185.7M | $130.3M | $583.0M | $736.7M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M |
| Capital expenditures | $1.1M | $5.8M | $14.0M | $13.6M | $12.8M |
| Depreciation & amortization | $9.8M | $10.3M | $9.0M | $7.6M | $6.9M |
| Share-based compensation | $80.2M | $154.3M | $134.1M | $91.4M | $47.0M |
| Change in accounts receivable | $951.0K | -$27.9M | $32.7M | $1.7M | -$99.0K |
| Change in accounts payable | $6.0M | $6.8M | $2.5M | -$4.6M | $529.0K |
| Purchases of investments | $322.5M | $935.6M | $904.5M | $429.0M | $1.02B |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NTLA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 32 filers
Held by These Filers89.8%
Shares Outstanding133,480,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 16,875,684 | $285.5M | 12.64% | +16.3% | 2026-08-14 |
| BlackRock, Inc. | 15,409,023 | $260.7M | 11.54% | +26.8% | 2026-08-07 |
| State Street Corp | 9,234,987 | $156.3M | 6.92% | +33.4% | 2026-08-07 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,332,401 | $124.1M | 5.49% | +17.8% | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 6,443,323 | $109.0M | 4.83% | +12.5% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,028,586 | $102.0M | 4.52% | +18.6% | 2026-06-30 |
| TWO SIGMA INVESTMENTS, LP | 5,235,348 | $88.6M | 3.92% | +11.3% | 2026-08-07 |
| FMR LLC | 4,773,034 | $80.8M | 3.58% | +130.9% | 2026-08-13 |
| RA CAPITAL MANAGEMENT, L.P. | 4,526,926 | $76.6M | 3.39% | +0.0% | 2026-08-14 |
| Regeneron Pharmaceuticals, Inc. | 3,702,995 | $62.7M | 2.77% | +0.0% | 2026-08-07 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,631,061 | $61.4M | 2.72% | +27.3% | 2026-08-12 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,280,760 | $55.5M | 2.46% | +134.8% | 2026-08-13 |
| Sumitomo Mitsui Trust Group, Inc. | 2,897,529 | $49.0M | 2.17% | +46.9% | 2026-07-30 |
| Amova Asset Management Americas, Inc. | 2,897,529 | $49.0M | 2.17% | +46.9% | 2026-08-13 |
| DIMENSIONAL FUND ADVISORS LP | 2,602,944 | $44.0M | 1.95% | +12.3% | 2026-08-11 |
| Goldman Sachs Group Inc | 2,264,471 | $38.3M | 1.70% | +39.1% | 2026-08-14 |
| UBS Group AG | 2,152,912 | $36.4M | 1.61% | -20.0% | 2026-08-13 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 2,066,356 | $35.0M | 1.55% | +28.2% | 2026-08-14 |
| Contrarius Group Holdings Ltd | 1,955,228 | $33.1M | 1.46% | +2.3% | 2026-08-11 |
| JUPITER ASSET MANAGEMENT LTD | 1,849,507 | $31.3M | 1.39% | +3.8% | 2026-08-10 |
| Morgan Stanley | 1,731,905 | $29.3M | 1.30% | -16.8% | 2026-08-11 |
| ARMISTICE CAPITAL, LLC | 1,500,000 | $25.4M | 1.12% | +346.4% | 2026-08-14 |
| RENAISSANCE TECHNOLOGIES LLC | 1,400,004 | $23.7M | 1.05% | +0.0% | 2026-08-13 |
| Northern Trust Corp | 1,272,136 | $21.5M | 0.95% | +31.7% | 2026-08-12 |
| HRT FINANCIAL LP | 1,243,317 | $21.0K | 0.93% | +147.5% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-05 to 2026-10-02
Recent transactions
- Insiders have net sold 39,968 shares over the last 182 days, across 0 purchases and 6 sales.
- Most recent: Dube Michael P (VP, Chief Accounting Officer) — Open market sale of 1,864 shares on 2026-10-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)39,968 sh(6 txns)
Net Shares-39,968
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer | Open market sale | 2026-10-02 | 1,864 |
| LEONARD JOHN M | President and CEO | Open market sale | 2026-08-21 | 2,785 |
| Dulac Edward J III | EVP, Chief Financial Officer | Open market sale | 2026-07-22 | 8,111 |
| Verwiel Frank | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| Keresty Georgia | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| GOODMAN JESSE | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| Goff Brian | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| Cohen Fred E | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| CHASE WILLIAM J | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| Bhanji Muna | Reporting person | Grant / award | 2026-06-09 | 9,200 |
| BASTA JAMES | EVP, General Counsel | Open market sale | 2026-03-02 | 1,211 |
| Clark Eliana | EVP, Chief Technical Officer | Open market sale | 2026-03-02 | 607 |
| Lebwohl David | EVP, Chief Medical Officer | Grant / award | 2026-03-01 | 9,943 |
| Schultes Birgit C | EVP, Chief Scientific Officer | Grant / award | 2026-03-01 | 39,200 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | VP, Chief Accounting Officer | Open market sale | 1,864 | $12.43 |
| 2026-08-21 | LEONARD JOHN M | President and CEO | Open market sale | 2,785 | $13.00 |
| 2026-08-20 | LEONARD JOHN M | President and CEO | Open market sale | 19,890 | $12.60 |
| 2026-07-22 | Dulac Edward J III | EVP, Chief Financial Officer | Open market sale | 8,111 | $11.25 |
| 2026-07-02 | Dulac Edward J III | EVP, Chief Financial Officer | Open market sale | 4,677 | $18.00 |
| 2026-07-01 | Dube Michael P | VP, Chief Accounting Officer | Open market sale | 2,641 | $16.78 |
| 2026-06-09 | Verwiel Frank | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | Keresty Georgia | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | GOODMAN JESSE | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | Goff Brian | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | Cohen Fred E | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | CHASE WILLIAM J | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-06-09 | Bhanji Muna | Reporting person | Grant / award | 9,200 | $0.00 |
| 2026-03-02 | BASTA JAMES | EVP, General Counsel | Open market sale | 1,211 | $13.78 |
| 2026-03-02 | Clark Eliana | EVP, Chief Technical Officer | Open market sale | 607 | $13.78 |
| 2026-03-01 | LEONARD JOHN M | President and CEO | Grant / award | 156,400 | $0.00 |
| 2026-03-01 | BASTA JAMES | EVP, General Counsel | Grant / award | 46,080 | $0.00 |
| 2026-03-01 | Lebwohl David | EVP, Chief Medical Officer | Grant / award | 9,943 | $0.00 |
| 2026-03-01 | Dulac Edward J III | EVP, Chief Financial Officer | Grant / award | 61,280 | $0.00 |
| 2026-03-01 | Schultes Birgit C | EVP, Chief Scientific Officer | Grant / award | 39,200 | $0.00 |
| 2026-03-01 | Clark Eliana | EVP, Chief Technical Officer | Grant / award | 7,353 | $0.00 |
| 2026-03-01 | Dube Michael P | VP, Chief Accounting Officer | Grant / award | 17,250 | $0.00 |
| 2026-01-05 | LEONARD JOHN M | President and CEO | Open market sale | 34,146 | $9.21 |
| 2026-01-05 | Schultes Birgit C | EVP, Chief Scientific Officer | Open market sale | 8,508 | $9.21 |
| 2026-01-05 | BASTA JAMES | EVP, General Counsel | Open market sale | 10,397 | $9.21 |
| 2026-01-05 | Cohen Fred E | Reporting person | Open market purchase | 150,000 | $9.35 |
| 2026-01-05 | Lebwohl David | EVP, Chief Medical Officer | Open market sale | 11,903 | $9.21 |
| 2026-01-05 | Clark Eliana | EVP, Chief Technical Officer | Open market sale | 9,515 | $9.21 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:13 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-04 | 8-K | 2026-09-04 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-24 | 4 | 2026-07-22 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-13 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about NTLA (Intellia Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Yahoo · 2026-10-21 -
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history
Yahoo Finance Singapore · 2026-10-21 -
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Yahoo · 2026-10-20 -
Is Intellia Therapeutics (NTLA) Cheap Or Pricey On Its New Chief Medical Officer Appointment?
Simply Wall Street · 2026-10-18 -
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance
Yahoo · 2026-10-18 -
NTLA Apr 2027 7.000 put (NTLA270416P00007000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-16 -
NTLA Oct 2026 24.000 call (NTLA261016C00024000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-16
No headlines in this category right now — try “All”.